Results 61 to 70 of about 22,482 (226)

Comparison of Loading Doses of Ziv-Aflibercept and Aflibercept in Neovascular Age-Related Macular Degeneration [PDF]

, 2020
Purpose:The aim of this study was to compare outcomes of 3 loading doses of ziv-aflibercept and aflibercept in treatment-naïve neovascular age-related macular degeneration (nAMD).Design:Retrospective, nonrandomized, comparative study.Methods:This was a ...
Subramanyam, Anand, Pandey, Priti, Chhablani, Jay Kumar, Abhishek Heranjal, Apoorva Ayachit, Tiwari, Sarvesh, Jay Chhablani, Heranjal, Abhishek, Sarvesh Tiwari, Salti, Haytham I.S., Priti Pandey, Ahmad Mansour, Ayachit, Apoorva G., Mansour, Ahmad Mohammed Farid Mahmoud, Chattannavar, Goura, Goura Chattannavar, Mohamad A Mansour, Sumit Randhir Singh, Anand Subramanyam, Haitham Salti, Singh, Sumit Randhir, Mansour, Mohamad A.   +21 more
core   +1 more source

Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration

Graefe's Archive for Clinical and Experimental Ophthalmology
To report short-term outcomes of treatment switch to faricimab in real-world patients with aflibercept-resistant neovascular age-related macular degeneration (AMD).
Miklos Schneider, Jakob Bjerager, Delila Hodzic-Hadzibegovic, O. Klefter, Y. Subhi, J. Hajari   +5 more
semanticscholar   +1 more source

Visual acuity is reduced with increasing central retinal thickness, but also with higher age and female sex in diabetic macular oedema

Acta Ophthalmologica, EarlyView.
Abstract Introduction The increasing number of patients with diabetes has increased the incidence of diabetic macular oedema (DME) with the accompanying risk of developing visual loss. The purpose of the present study was to describe the contributions of increased central retinal thickness (CRT) and other risk factors to the reduction in visual acuity ...
Signe Krejberg Jeppesen, Toke Bek
wiley   +1 more source

Plain language summary of publication of the 96-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema

Therapeutic Advances in Ophthalmology
Summary What is this summary about? This is a summary of a publication about the 2-year (96-week) results from the PHOTON study, which was published in Ophthalmology . Diabetic macular edema (DME) is a leading cause of vision loss in people with diabetes.
Diana V. Do, Charles C. Wykoff, Sobha Sivaprasad, David M. Brown, David S. Boyer, Taiji Sakamoto, Peter Win, Sunir Joshi, Hani Salehi-Had, András Seres, Sergio Leal, Robert Vitti, Karen W. Chu, Kimberly Reed, Yenchieh Cheng, Rafia Bhore, Zhanying Bai, Ursula Schmidt-Ott, Thomas Schmelter, Andrea Schulze, Zoran Hasanbasic, Peter J. Morgan-Warren, Xin Zhang, Alyson J. Berliner   +23 more
doaj   +1 more source

Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration

Japanese Journal of Ophthalmology
To evaluate short-term outcomes of intravitreal injection of aflibercept 8 mg for neovascular age-related macular degeneration (nAMD). Retrospective, interventional case series.
H. Matsumoto, Junki Hoshino, Saki Numaga, Kaori Mimura, Yosuke Asatori, Hideo Akiyama   +5 more
semanticscholar   +1 more source

Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.

Journal of the American Medical Association (JAMA), 2023
Importance Anti-vascular endothelial growth factor (VEGF) injections in eyes with nonproliferative diabetic retinopathy (NPDR) without center-involved diabetic macular edema (CI-DME) reduce development of vision-threatening complications from diabetes ...
R. Maturi, A. Glassman, Kristin Josic, C. Baker, Adam T. Gerstenblith, L. Jampol, A. Meleth, Daniel F. Martin, M. Melia, O. Punjabi, S. Rofagha, H. Salehi-Had, Cynthia R. Stockdale, Jennifer K. Sun   +13 more
semanticscholar   +1 more source

Cost-effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration and its Subtypes from the Societal and Patient Perspectives in Japan

Ophthalmology and Therapy
Introduction This study evaluated the cost-effectiveness of anti-vascular endothelial growth factor (VEGF) therapies for subtypes of neovascular age-related macular degeneration (nAMD) from the societal perspective, and for any nAMD from the patient ...
Yasuo Yanagi, Kanji Takahashi, Tomohiro Iida, Fumi Gomi, Hiroshi Onishi, Junko Morii, Taiji Sakamoto   +6 more
doaj   +1 more source

Comparative study between ranibizumab and aflibercept in the management of macular edema caused by diabetes mellitus in age group more than 40 years

Al-Azhar Assiut Medical Journal, 2019
Background Diabetic macular edema (DME) is a common cause of blindness and visual impairment in diabetic patients, which can affect the quality of life.
Abd El-Magid M Tag El-Din
doaj   +1 more source

Intravitreal Aflibercept as a Rescue Therapy for Retinal Neovascularization and Macular Edema due to Eales Disease

Case Reports in Ophthalmological Medicine, 2021
We report the rescue effect of intravitreal aflibercept injections on retinal neovascularization and macular edema due to Eales disease. Case 1 was a 36-year-old female. Intravitreal aflibercept was administered as rescue therapy after persistent retinal
Ning-Yi Hsia, Chun-Ju Lin, Chun-Ting Lai, Henry Bair, Cheng-Hsien Chang, Jane-Ming Lin, Yi-Yu Tsai   +6 more
doaj   +1 more source

Randomized Trial of Biosimilar ABP 938 Compared with Reference Aflibercept in Adults with Neovascular Age-related Macular Degeneration.

Ophthalmology Retina
PURPOSE To evaluate the clinical efficacy, safety, and immunogenicity of biosimilar ABP 938 compared with aflibercept reference product (RP) in adults with neovascular (wet) age-related macular degeneration (nAMD).
Scott M. Friedman, N. London, J. Hamouz, Á. Kerényi, András Papp, T. Pregun, V. Chow, Bianca Bautista, Daidong Wang, Gary Grachev, J. Franklin   +10 more
semanticscholar   +1 more source